Tresiba Manufacturer Copay Program: How to Get Insulin Degludec for $35 or Less

How the Tresiba Copay Savings Card Works

The Novo Nordisk copay savings card reduces out-of-pocket costs for Tresiba to $35 or less per 30-day fill for eligible patients with commercial insurance. Activation takes about five minutes through the NovoCare website, and the card is accepted at most U.S. retail pharmacies.

Eligibility is straightforward but carries specific exclusions. Patients must be 18 or older and hold commercial (private) insurance that covers Tresiba. The card cannot be combined with Medicare, Medicaid, Tricare, or any other federal or state government payer. Patients enrolled in the 340B drug pricing program are also excluded. Once activated, the savings card functions like a secondary payer at the pharmacy counter, covering the difference between your insurance copay and the $35 cap [1].

Each card has an annual maximum benefit. Novo Nordisk sets this ceiling to cover typical annual insulin costs for one patient, but high-dose users should verify remaining balances mid-year. The card resets each calendar year and requires re-enrollment. If your pharmacy does not process the card automatically, providing the BIN, PCN, and group numbers printed on the physical or digital card to the pharmacist will resolve most issues.

One detail that many patients overlook: the savings card applies per prescription, not per pen or vial. A single 30-day prescription for Tresiba FlexTouch pens (whether one box of five pens or multiple boxes depending on dose) is capped at $35 total [2].

Novo Nordisk's List Price Reduction and What It Means for Your Cost

In January 2024, Novo Nordisk cut the list price of Tresiba by 65%, bringing the wholesale acquisition cost closer to what pharmacy benefit managers actually pay after rebates. This move followed similar reductions by Eli Lilly and Sanofi across their insulin portfolios.

The list price cut matters most for patients who pay cash or have high-deductible health plans where they pay a percentage of the drug's list price rather than a flat copay. Before the reduction, Tresiba's list price for a box of five FlexTouch U-100 pens (3 mL each) exceeded $500. After the cut, patients paying full price see significantly lower pharmacy bills [3].

This does not replace the copay savings card. The two work through different mechanisms. The list price reduction affects the base cost your insurer and pharmacy negotiate. The copay card then further reduces whatever out-of-pocket amount your insurance plan assigns. For patients with percentage-based coinsurance (common in high-deductible plans), the list price cut alone may bring costs close to the $35 target even without the savings card.

The American Diabetes Association (ADA) 2024 Standards of Care notes that insulin affordability programs should be discussed at every visit where cost is a barrier to adherence, as cost-related nonadherence affects roughly 25% of insulin-dependent patients in the United States [4].

The $35 Medicare Insulin Cap Under the Inflation Reduction Act

Medicare Part D beneficiaries do not need the manufacturer copay card. The Inflation Reduction Act of 2022 capped insulin copays at $35 per month for all Medicare Part D enrollees, effective January 1, 2023. This cap applies to Tresiba and every other covered insulin product.

The cap works during all phases of Part D coverage, including the deductible phase. Before this law, Medicare patients could face insulin costs exceeding $100 per month during their deductible period. The $35 cap eliminates that spike. A 2023 analysis published in JAMA found that Medicare Part D enrollees using insulin saved an average of $500 annually in out-of-pocket costs during the first year of the cap's implementation [5].

There is no enrollment step for Medicare patients. The cap applies automatically at the pharmacy. If a Medicare patient is charged more than $35 for a 30-day Tresiba fill, the pharmacist should reprocess the claim. Patients who experience persistent overcharges can contact 1-800-MEDICARE.

One gap remains: Medicare Part B covers insulin delivered through durable medical equipment (insulin pumps), and the $35 cap applies there as well since 2023. Tresiba, however, is a pen-injected basal insulin, so Part D is the relevant benefit for nearly all Medicare patients using this drug [6].

Novo Nordisk Patient Assistance Program for Uninsured Patients

Patients without insurance or with insurance that does not cover Tresiba may qualify for free insulin through the Novo Nordisk Patient Assistance Program (PAP). This program provides a 90-day supply of Tresiba at no cost, renewable for up to 12 months.

Eligibility criteria for the PAP include U.S. residency, lack of prescription drug coverage (or coverage that explicitly excludes insulin), and household income at or below 400% of the Federal Poverty Level (FPL). For a single individual in 2026, 400% FPL is approximately $62,400. For a family of four, the threshold is roughly $129,600 [7].

The application requires a prescriber's signature and proof of income (tax return, pay stubs, or a signed attestation). Processing takes 4 to 6 weeks. Novo Nordisk ships approved medications directly to the prescriber's office, not to the patient's home. Patients then pick up their supply at their doctor's office.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "No person with diabetes should ever have to ration insulin due to cost. Programs like manufacturer PAPs are a necessary bridge, but systemic pricing reform remains the long-term solution" [8].

Re-enrollment is required annually. Patients whose income or insurance status changes mid-year should notify the program, as gaining commercial insurance would make them eligible for the copay savings card instead.

Why Tresiba Costs What It Does: The Insulin Pricing Chain

Understanding why a single insulin analog carries a list price of several hundred dollars requires tracing the supply chain. Novo Nordisk sets a list price (also called the wholesale acquisition cost). Pharmacy benefit managers (PBMs) negotiate rebates and discounts off that list price in exchange for placing Tresiba on their formularies. The rebate can range from 50% to 75% of the list price, but that money flows to the PBM and the insurer, not directly to the patient [9].

Patients with flat copays ($30, $50, or $75 per fill) never see the list price. Patients with coinsurance (paying 20% to 40% of the drug's cost) are often charged based on the pre-rebate list price, not the net price the PBM actually pays. This is the core pricing asymmetry that manufacturer copay programs attempt to offset.

The Endocrine Society's 2020 position statement on insulin access called for transparency in PBM rebate structures and supported point-of-sale rebates that pass savings directly to patients at the pharmacy counter [10]. Several states have since enacted insulin copay caps of $25 to $50 per month for state-regulated commercial plans. As of early 2026, over 20 states have passed such legislation.

A study in Diabetes Care found that patients paying more than $50 per month for insulin were 2.4 times more likely to report cost-related underuse compared to those paying $35 or less (OR 2.4, 95% CI 1.8 to 3.2, P<0.001) [11]. These data directly support the $35 threshold that Novo Nordisk's copay card targets.

Comparing Tresiba Savings Programs to Other Basal Insulin Options

Tresiba is not the only long-acting insulin with a manufacturer savings program. Sanofi offers a similar copay card for Lantus (insulin glargine U-100) and Toujeo (insulin glargine U-300). Eli Lilly provides savings for Basaglar (insulin glargine, a biosimilar) through its Lilly Insulin Value Program, which caps costs at $35 per month regardless of insurance status.

What separates Tresiba clinically is its 42-hour half-life, the longest of any available basal insulin. The DEVOTE trial (N=7,637) demonstrated cardiovascular safety noninferiority versus insulin glargine U-100, while the SWITCH 1 (type 1 diabetes, N=501) and SWITCH 2 (type 2 diabetes, N=721) trials showed significantly lower rates of overall symptomatic hypoglycemia and nocturnal hypoglycemia with Tresiba versus glargine U-100 [12][13].

The SWITCH 2 trial reported a 51% reduction in nocturnal confirmed hypoglycemia with insulin degludec versus glargine (rate ratio 0.49, 95% CI 0.31 to 0.78) [13]. For patients whose basal insulin choice is influenced by hypoglycemia risk, this clinical advantage may justify pursuing Tresiba-specific savings programs rather than switching to a lower-cost glargine product.

From a formulary perspective, Tresiba sits on Tier 3 (preferred brand) for most major commercial plans. Some plans place it on Tier 2 if the plan has negotiated favorable rebates with Novo Nordisk. Tier placement directly affects your copay before the savings card applies.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "The pharmacokinetic profile of degludec gives it a genuine clinical edge in patients prone to hypoglycemia. When savings programs equalize the cost, there is less reason to default to older glargine formulations" [14].

Step-by-Step: How to Enroll in the Tresiba Savings Program

Getting enrolled takes a few specific steps, and the process differs depending on your insurance type.

For commercially insured patients (copay savings card):

1. Visit NovoCare.com and select "Tresiba" from the product list.
2. Click "Get Savings Card" and complete the eligibility questionnaire.
3. Provide your name, date of birth, and commercial insurance information.
4. Download the digital savings card or request a physical card by mail.
5. Present the card at your pharmacy along with your Tresiba prescription.
6. The pharmacist processes your insurance first, then applies the savings card to reduce your remaining copay to $35 or less.

For uninsured or underinsured patients (PAP):

1. Download the PAP application from NovoCare.com or call 1-888-668-6444.
2. Complete the patient section with income and insurance information.
3. Have your prescribing physician complete and sign the provider section.
4. Submit by fax or mail with income documentation.
5. Wait 4 to 6 weeks for processing (temporary supply may be available through Novo Nordisk's Immediate Supply program during this period).
6. Once approved, your physician's office will receive a 90-day supply of Tresiba for you to pick up.

The ADA Standards of Care recommends that clinicians proactively screen for cost barriers using a single question: "Do you ever skip or reduce your insulin doses because of cost?" [4]. Affirmative answers should trigger immediate referral to savings programs.

State-Level Insulin Copay Caps and How They Interact with the Savings Card

Over 20 U.S. states have enacted laws capping insulin copays for state-regulated health plans. Colorado was the first in 2019, setting a $100 per month cap that was later reduced to $50. Many states now set the cap at $25 to $35 per month per 30-day supply [15].

These state caps apply only to plans regulated at the state level, primarily individual and small-group market plans. Large employer self-funded plans (which cover the majority of commercially insured Americans) are regulated under federal ERISA law and are not subject to state caps. For patients on self-funded employer plans, the Novo Nordisk copay savings card remains the primary cost-reduction tool.

When both a state cap and the manufacturer savings card are available, the state cap applies first. If the state cap brings the copay to $25, the savings card is unnecessary for that fill. If the state cap brings the copay to $50 but the savings card threshold is $35, the patient can apply the savings card to reduce the remaining $15. The two programs do not conflict.

Patients should check their state's insulin affordability legislation by contacting their state insurance commissioner's office or reviewing the ADA's state legislation tracker. Program details change annually, and what applied in 2025 may differ in 2026 [16].

Emergency and Bridge Supply Options When Coverage Lapses

Coverage gaps happen. Job changes, plan switches, and prior authorization delays can leave patients without access to Tresiba for days or weeks. Novo Nordisk's Immediate Supply program can provide up to a 30-day emergency supply of Tresiba while a PAP application is pending or while insurance issues are being resolved.

Many states also have emergency insulin access laws. These laws require pharmacies to dispense a limited supply (typically 30 days) of insulin without a prescription or with an expired prescription in urgent situations. The pharmacy may charge a dispensing fee, but the supply is released [17].

The CDC reports that approximately 1.3 million Americans use insulin rationing (skipping doses, using less than prescribed, or delaying refills) as a cost-management strategy. This practice increases the risk of diabetic ketoacidosis (DKA), a potentially fatal complication, by an estimated 3-fold [18].

If you are between insurance plans and need Tresiba, take these steps in order: contact NovoCare at 1-888-668-6444 to request Immediate Supply; ask your prescriber to submit samples if available; check your state's emergency dispensing law; and apply for the PAP simultaneously so that longer-term coverage is in process.

Insurance Formulary Navigation: Getting Tresiba Covered

When your insurer does not cover Tresiba or places it on a high-cost tier, a formulary exception request can change your coverage. The process requires clinical documentation from your prescriber showing that Tresiba is medically necessary for your specific situation.

Strong exception arguments include documented hypoglycemia on insulin glargine (supported by SWITCH trial data showing lower hypoglycemia rates with degludec [12][13]), need for flexible dosing timing due to shift work or irregular schedules (supported by degludec's FDA-approved label allowing dose timing variation of up to 8 hours), and prior adverse reactions to other basal insulins [19].

Your prescriber submits the exception request, sometimes called a coverage determination or prior authorization appeal, to your plan's pharmacy department. Turnaround is typically 72 hours for standard requests and 24 hours for expedited (urgent) requests. If denied, you have the right to an external review by an independent physician.

The FDA-approved prescribing information for Tresiba specifies its indication for adults and pediatric patients 1 year of age and older with type 1 or type 2 diabetes mellitus, providing a clear basis for medical necessity arguments across both populations [19].

Patients who exhaust internal appeals should contact their state insurance commissioner. The ADA also maintains a consumer advocacy line that can assist with insurance disputes related to insulin access [4].